啁啾声诱发耳声发射与中耳吸光度用于囊性纤维化患者耳毒性监测
本研究采用纵向设计,对91例接受耳毒性药物(如妥布霉素)的囊性纤维化(CF)患者进行听力监测,并与37例正常听力青年对照比较。结果显示,所有三种瞬态诱发耳声发射(TEOAE)条件均有助于区分CF患者中听力正常与感音神经性听力损失的耳,受试者工作特征曲线下面积在2.8至8 kHz频带为0.78至0.92。联合使用TEOAE与吸光度有潜力解释听阈波动,尤其适用于病情严重无法进行行为测听的患者。
要点
- TEOAE三种条件均能区分CF患者听力正常与感音神经性听力损失的耳,AUC为0.78至0.92(2.8至8 kHz)。
- 联合TEOAE与宽频吸光度可解释因耳蜗或中耳功能变化引起的听阈波动。
- 吸光度测量可识别一例暂时性听力损失耳在5.7 kHz的潜在中耳功能障碍。
核心结论
- 联合使用TEOAE与吸光度有潜力解释听阈波动,并鼓励将二者用于耳毒性监测,尤其适用于病情严重无法行为测听的患者。
- 需要在更多接受耳毒性药物的CF患者中进行额外纵向研究,以进一步评估这些措施在耳毒性监测方案中的临床效用。
研究设计与样本
- 纵向研究设计,监测91例接受已知耳毒性药物(如妥布霉素)的CF患者(中位年龄25岁,范围15至63岁)。
- 结果与37例无CF或类似治疗史的正常听力青年(中位年龄32.5岁,范围18至65岁)比较。
主要发现
- 初始就诊时,CF患者157耳中76耳(48%)听力正常,81耳(52%)至少一个频率存在感音神经性听力损失。
- 4例患者的7耳在研究参与期间有≥3次就诊确认的行为听阈变化。
- 所有三种TEOAE条件均有助于区分CF听力正常耳与感音神经性听力损失耳,2.8至8 kHz频带的AUC为0.78至0.92。
- 吸光度测量可识别一例暂时性听力损失耳在5.7 kHz的潜在中耳功能障碍。
临床怎么用
- TEOAE与宽频吸光度客观测试可联合用于耳毒性监测,尤其适用于病情严重无法进行行为听力测试的患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of this study was to investigate the use of transient-evoked otoacoustic emissions (TEOAEs) and middle ear absorbance measurements to monitor auditory function in patients with cystic fibrosis (CF) receiving ototoxic medications. TEOAEs were elicited with a chirp stimulus using an extended bandwidth (0.71 to 8 kHz) to measure cochlear function at higher frequencies than traditional TEOAEs. Absorbance over a wide bandwidth (0.25 to 8 kHz) provides information on middle ear function. The combination of these time-efficient measurements has the potential to identify early signs of ototoxic hearing loss. DESIGN: A longitudinal study design was used to monitor the hearing of 91 patients with CF (median age = 25 years; age range = 15 to 63 years) who received known ototoxic medications (e.g., tobramycin) to prevent or treat bacterial lung infections. Results were compared to 37 normally hearing young adults (median age = 32.5 years; age range = 18 to 65 years) without a history of CF or similar treatments. Clinical testing included 226-Hz tympanometry, pure-tone air-conduction threshold testing from 0.25 to 16 kHz and bone conduction from 0.25 to 4 kHz. Experimental testing included wideband absorbance at ambient and tympanometric peak pressure and TEOAEs in three stimulus conditions: at ambient pressure and at tympanometric peak pressure using a chirp stimulus with constant incident pressure level across frequency and at ambient pressure using a chirp stimulus with constant absorbed sound power across frequency. RESULTS: At the initial visit, behavioral audiometric results indicated that 76 of the 157 ears (48%) from patients with CF had normal hearing, whereas 81 of these ears (52%) had sensorineural hearing loss for at least one frequency. Seven ears from four patients had a confirmed behavioral change in hearing threshold for ≥3 visits during study participation. Receiver operating characteristic curve analyses demonstrated that all three TEOAE conditions were useful for distinguishing CF ears with normal hearing from ears with sensorineural hearing loss, with an area under the receiver operating characteristic curve values ranging from 0.78 to 0.92 across methods for frequency bands from 2.8 to 8 kHz. Case studies are presented to illustrate the relationship between changes in audiometric thresholds, TEOAEs, and absorbance across study visits. Absorbance measures permitted identification of potential middle ear dysfunction at 5.7 kHz in an ear that exhibited a temporary hearing loss. CONCLUSIONS: The joint use of TEOAEs and absorbance has the potential to explain fluctuations in audiometric thresholds due to changes in cochlear function, middle ear function, or both. These findings are encouraging for the joint use of TEOAE and wideband absorbance objective tests for monitoring ototoxicity, particularly, in patients who may be too ill for behavioral hearing tests. Additional longitudinal studies are needed in a larger number of CF patients receiving ototoxic drugs to further evaluate the clinical utility of these measures in an ototoxic monitoring program.
引用
- Garinis AC, Keefe DH, Hunter LL, et al. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients. Ear Hear. 2018. PMID: 28708814. doi:10.1097/AUD.0000000000000464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。